Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2145 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-04

Study Completion Date

2018-07-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Robot-assisted vs VATS Lobectomy for NSCLC

NCT03134534

Pulmonary Neoplasm

COMPLETED NA

A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer

NCT03427567

Non-small Cell Lung Cancer

COMPLETED

Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)

NCT01337037

Lung Cancer

UNKNOWN

Treatment of Early Stage Lung Cancer by VATS Versus OPEN Lobectomy

NCT01933828

Lung Cancer

UNKNOWN NA

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)

NCT03786003

Carcinoma, Non-Small-Cell Lung

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on patient demographic, clinical characteristics, treatment and clinical outcomes will be collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy for pathologic N2 NSCLC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VATS lobectomy

Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery

VATS lobectomy

Intervention Type PROCEDURE

Patients who received lobectomy by video-assisted thoracoscopic surgery

Thoracotomy lobectomy

Pathologic N2 NSCLC patients who received lobectomy by thoracotomy

Thoracotomy lobectomy

Intervention Type PROCEDURE

Patients who received lobectomy by thoracotomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VATS lobectomy

Patients who received lobectomy by video-assisted thoracoscopic surgery

Intervention Type PROCEDURE

Thoracotomy lobectomy

Patients who received lobectomy by thoracotomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with age \> 18 years old;
* Patients with pathologically diagnosed non-small cell lung cancer;
* Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017;
* Patients who received lymphadenectomy for all accessible lymph nodes;
* Patients with N2 lymph nodes (+) after surgeries;

Exclusion Criteria

* Patients with second primary tumors or multiple primary tumors;
* Patients who received chest surgeries before hospitalization;
* Patients with superior pulmonary sulcus tumor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No